Literature DB >> 20864552

Renal cell carcinomas in haemodialysis patients: does haemodialysis duration influence pathological cell types and prognosis?

Naoto Sassa1, Ryohei Hattori, Toyonori Tsuzuki, Yoshihiko Watarai, Akitoshi Fukatsu, Satoshi Katsuno, Tosinori Nishikimi, Takashi Fujita, Kenji Ohmae, Momokazu Gotoh.   

Abstract

BACKGROUND: It is well known that renal cell carcinoma (RCC) is one of the most important complications in haemodialysis (HD) patients. However, the influence of HD duration on the development of RCCs has not yet been described. This study sought to determine whether HD duration is related to pathological RCC types and to prognosis.
METHODS: We examined 69 patients having HD (73 kidneys) who underwent radical nephrectomy for renal tumours between 1991 and 2008. We divided the patients into three groups according to the duration of HD (< 10 years, between 10 and 20 years, and > 20 years). All histological examinations were performed without knowledge of clinical outcomes. In each case, pathological cell types and clinical parameters were recorded.
RESULTS: The patients with HD duration of > 10 years showed distinct pathological characteristics, including acquired cystic disease of kidney-associated RCCs. The disease-free survival (DFS) rates of these groups were statistically different from one another (P < 0.05). RCC with a sarcomatoid component was found in cases having HD durations of > 10 years. The DFS rate of the patients with a sarcomatoid component was 55.9% at 5 years and 37.3% at 10 years.
CONCLUSIONS: HD duration influenced pathological cell types and tumour stages of RCCs in HD patients. Patients receiving > 10 years of HD experienced RCCs with a sarcomatoid component, which resulted in poor outcomes. Hence, patients receiving long-term HD, and especially those with > 10 years of HD, should have frequent and careful medical examinations.

Entities:  

Mesh:

Year:  2010        PMID: 20864552     DOI: 10.1093/ndt/gfq529

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  5 in total

1.  Outcome of advanced renal cell carcinoma arising in end-stage renal disease: comparison with sporadic renal cell carcinoma.

Authors:  Hiroki Ishihara; Hironori Fukuda; Hidekazu Tachibana; Kazuhiko Yoshida; Hirohito Kobayashi; Toshio Takagi; Junpei Iizuka; Hideki Ishida; Yoji Nagashima; Tsunenori Kondo; Kazunari Tanabe
Journal:  Clin Exp Nephrol       Date:  2021-02-27       Impact factor: 2.801

Review 2.  Risk of chronic kidney disease after cancer nephrectomy.

Authors:  Lin Li; Wei Ling Lau; Connie M Rhee; Kevin Harley; Csaba P Kovesdy; John J Sim; Steve Jacobsen; Anthony Chang; Jaime Landman; Kamyar Kalantar-Zadeh
Journal:  Nat Rev Nephrol       Date:  2014-01-14       Impact factor: 28.314

3.  Comparison of prognosis between patients with renal cell carcinoma on hemodialysis and those with renal cell carcinoma in the general population.

Authors:  Yasunobu Hashimoto; Toshio Takagi; Tsunenori Kondo; Junpei Iizuka; Hirohito Kobayashi; Kenji Omae; Kazuhiko Yoshida; Kazunari Tanabe
Journal:  Int J Clin Oncol       Date:  2015-03-12       Impact factor: 3.402

4.  Detection and management of renal cell carcinoma in the renal allograft.

Authors:  Gyula Végső; Éva Toronyi; Pál Ákos Deák; Attila Doros; Róbert Miklós Langer
Journal:  Int Urol Nephrol       Date:  2012-09-01       Impact factor: 2.370

5.  Sex differences in the development of malignancies among end-stage renal disease patients: a nationwide population-based follow-up study in Taiwan.

Authors:  Chi-Jung Chung; Chao-Yuan Huang; Hung-Bin Tsai; Chih-Hsin Muo; Mu-Chi Chung; Chao-Hsiang Chang; Chiu-Ching Huang
Journal:  PLoS One       Date:  2012-09-05       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.